WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer products using its
Targeted Antibody Payload (TAP) technology and antibody expertise, today
announced that the Company will host a conference call at 8:00 a.m. ET
on Friday, October 26, 2012, to discuss ImmunoGen's financial results
for the three-month period ended September 30, 2012 — the first quarter
of the Company's 2013 fiscal year. Management also will provide an
update on the Company and more information about the economic terms of
the trastuzumab emtansine (T-DM1)-related license with Genentech, a
member of the Roche Group.
To access the live call by phone, dial 913-312-1472. Passcode: 4483380.
The call also may be accessed through the Investor Information section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through November 9, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's TAP
technology uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-killing agents specifically to tumor cells. There are
now ten TAP compounds in clinical development, of which three are wholly
owned by the Company. Marketing applications for trastuzumab emtansine
(T-DM1), the most advanced compound using ImmunoGen's TAP technology,
have been submitted in the US and Europe. Roche is developing this
compound globally under an agreement between ImmunoGen and Genentech, a
member of the Roche Group. More information about ImmunoGen can be found
Carol Hausner, 781-895-0600
Director, Investor Relations and Corporate Communications
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media